Cancer Research and Treatment

Original Articles

Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients: Andreas D. Hartkopf, Markus Wallwiener, Markus Hahn, Tanja N. Fehm, Sara Y. Brucker, Florin-Andrei Taran; Cancer Res Treat. 2016;48(1):115-124. Published online February 16, 2015; DOI: https://doi.org/10.4143/crt.2014.287

Purpose
Disseminated tumor cells (DTCs) from bone marrow (BM) are a surrogate of minimal residual disease (MRD) in primary breast cancer (PBC) patients and associated with an adverse prognosis. However, BM sampling is an invasive procedure. Although there is growing evidence that circulating tumor cells (CTCs) from the blood are also suitable for monitoring MRD, data on the simultaneous detection of DTCs and CTCs are limited. Materials and Methods We determined the presence of DTCs using immunocytochemistry and the pan-cytokeratin antibody A45-B/B3. CTCs were determined simultaneously using a reverse transcriptionpolymerase chain reaction–based assay (AdnaTest Breast Cancer) and CellSearch (at least one CTC per 7.5 mL blood). We compared the detection of DTCs and CTCs and evaluated their impact on disease-free and overall survival.
Results
Of 585 patients, 131 (22%) were positive for DTCs; 19 of 202 (9%) and 18 of 383 (5%) patients were positive for CTCs, as shown by AdnaTest and CellSearch, respectively. No significant association was observed between DTCs and CTCs (p=0.248 and p=0.146 as shown by AdnaTest and CellSearch, respectively). The presence of DTCs (p=0.046) and the presence of CTCs as shown by CellSearch (p=0.007) were predictive of disease-free survival. Conclusion Our data confirm the prognostic relevance of DTCs and CTCs in patients with PBC. As we found no significant relationship between DTCs and CTCs, prospective trials should include their simultaneous detection. Within those trials, the question of whether or not DTCs and CTCs are independent subpopulations of malignant cell clones should be determined by molecular characterization.

Citations

Citations to this article as recorded by

A comprehensive review and meta-analysis of CTC isolation methods in breast cancer
Alexey S. Rzhevskiy, Guzel R. Sagitova, Tamilla A. Karashaeva, Andrey O. Morozov, Anastasia S. Fatyanova, Vlada V. Kazantseva, Simon A. Joosse, Andrei V. Zvyagin, Majid Ebrahimi Warkini
Critical Reviews in Oncology/Hematology.2025; 206: 104579. CrossRef
High serum levels of leucine-rich α-2 glycoprotein 1 (LRG-1) are associated with poor survival in patients with early breast cancer
Andy Göbel, Tilman D. Rachner, Oliver Hoffmann, Daniel Martin Klotz, Sabine Kasimir-Bauer, Rainer Kimmig, Lorenz C. Hofbauer, Ann-Kathrin Bittner
Archives of Gynecology and Obstetrics.2024; 309(6): 2789. CrossRef
Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis
Silver Alkhafaji, Denise M. Wolf, Mark Jesus M. Magbanua, Laura J. van ‘t Veer, John W. Park, Laura Esserman, Rita A. Mukhtar
npj Breast Cancer.2024;[Epub] CrossRef
Correlation between Imaging Markers Derived from PET/MRI and Invasive Acquired Biomarkers in Newly Diagnosed Breast Cancer
Kai Jannusch, Ann-Kathrin Bittner, Nils Martin Bruckmann, Janna Morawitz, Cleo Stieglitz, Frederic Dietzel, Harald H. Quick, Hideo A. Baba, Ken Herrmann, Lale Umutlu, Gerald Antoch, Julian Kirchner, Sabine Kasimir-Bauer, Oliver Hoffmann
Cancers.2023; 15(6): 1651. CrossRef
The Role of Circulating Tumor Cells in Breast Cancer and Implications for Radiation Treatment Decisions
Chelain R. Goodman, Corey W. Speers
International Journal of Radiation Oncology*Biology*Physics.2021; 109(1): 44. CrossRef
Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis
Andreas D. Hartkopf, Sara Y. Brucker, Florin-Andrei Taran, Nadia Harbeck, Alexandra von Au, Bjørn Naume, Jean-Yves Pierga, Oliver Hoffmann, Matthias W. Beckmann, Lisa Rydén, Tanja Fehm, Rebecca Aft, Montserrat Solà, Vincent Walter, Brigitte Rack, Florian
European Journal of Cancer.2021; 154: 128. CrossRef
The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance
Hassan Dianat-Moghadam, Mehdi Azizi, Zahra Eslami-S, Luis Enrique Cortés-Hernández, Maryam Heidarifard, Mohammad Nouri, Catherine Alix-Panabières
Cancers.2020; 12(4): 867. CrossRef
The biology and clinical potential of circulating tumor cells
Taja Lozar, Klara Gersak, Maja Cemazar, Cvetka Grasic Kuhar, Tanja Jesenko
Radiology and Oncology.2019; 53(2): 131. CrossRef
The Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer Prior to any Systematic Therapy: A Systematic Review
Sepideh Mansouri, Parisa Mokhtari-Hesari, Fatemeh Naghavi-al-Hosseini, Keivan Majidzadeh-A, Leila Farahmand
Current Stem Cell Research & Therapy.2019; 14(6): 519. CrossRef
Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer
Mark Jesus M. Magbanua, Christina Yau, Denise M. Wolf, Jin Sun Lee, Aheli Chattopadhyay, Janet H. Scott, Erin Bowlby-Yoder, E. Shelley Hwang, Michael Alvarado, Cheryl A. Ewing, Amy L. Delson, Laura J. van't Veer, Laura Esserman, John W. Park
Clinical Cancer Research.2019; 25(17): 5388. CrossRef
Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy
Vincent P. Walter, Florin-Andrei Taran, Markus Wallwiener, Markus Hahn, Sara Y. Brucker, Andreas D. Hartkopf
Archives of Gynecology and Obstetrics.2018; 297(3): 785. CrossRef
Clinical applications of the CellSearch platform in cancer patients
Sabine Riethdorf, Linda O'Flaherty, Claudia Hille, Klaus Pantel
Advanced Drug Delivery Reviews.2018; 125: 102. CrossRef
DIsseminated tumor cells of luminal breast cancer patients .
D. A. Ryabchikov, O. A. Beznos, I. A. Dudina, I. K. Vorotnikov, D. A. Denchik, S. V. Chulkova, O. A. Talipov, N. N. Tupitsyn
Russian Journal of Biotherapy.2018; 17(1): 53. CrossRef
Enrichment and Molecular Analysis of Breast Cancer Disseminated Tumor Cells from Bone Marrow Using Microfiltration
Sreeraj G. Pillai, Peixuan Zhu, Chidananda M. Siddappa, Daniel L. Adams, Shuhong Li, Olga V. Makarova, Pete Amstutz, Ryan Nunley, Cha-Mei Tang, Mark A. Watson, Rebecca L. Aft, Harriet Wikman
PLOS ONE.2017; 12(1): e0170761. CrossRef
Clinical and biological significance of circulating tumor cells in cancer
Takaaki Masuda, Naoki Hayashi, Tomohiro Iguchi, Shuhei Ito, Hidetoshi Eguchi, Koshi Mimori
Molecular Oncology.2016; 10(3): 408. CrossRef
Seroma Cytology in Breast Cancer: An Underappreciated Issue
Huseyin Ozgur Aytac, Tarik Zafer Nursal, Tamer Çolakoğlu, Filiz Aka Bolat, Gökhan Moray
Clinical Breast Cancer.2016; 16(6): e187. CrossRef
Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients
Andreas D. Hartkopf, Florin-Andrei Taran, Christina B. Walter, Markus Hahn, Tanja Fehm, Markus Wallwiener, Sara Y. Brucker
Breast Cancer Research and Treatment.2015; 152(1): 51. CrossRef
Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients
Galatea Kallergi, Sofia Agelaki, Maria A. Papadaki, Dimitris Nasias, Alexios Matikas, Dimitris Mavroudis, Vassilis Georgoulias
Breast Cancer Research.2015;[Epub] CrossRef

15,327 View
86 Download
18 Web of Science
18 Crossref

Irradiation of Donor Mononuclear Cells for Treatment of Chemorefractory Metastatic Solid Cancers: A Community-Based Immune Transplant Pilot Study: John T. Reynolds, John M. Watkins, Tarek A. Dufan, Shrikant S. Kubsad; Cancer Res Treat. 2012;44(2):133-141. Published online June 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.2.133

Abstract PDF PubReader ePub

PURPOSE
Chemotherapy has demonstrated ability to generate tumor antigens secondary to induction of apoptosis, against which human leukocyte antigen-compatible, irradiated, related donor mononuclear cells may be administered with immune stimulation to activate antigen presenting and cytotoxic T cells, while minimizing risk of graft-versus-host disease (GVHD). The present study endeavours to describe feasibility and efficacy of this treatment, specifically in the community setting.
MATERIALS AND METHODS
Eligible patients had rapidly progressive, chemorefractory metastatic solid tumors. Treatment consisted of intravenous etoposide and cyclosporine for three days followed by granulocyte-macrophage colony-stimulating factor for 5 days. The following week, 5x10(7) haploidentical or more closely matched irradiated donor mononuclear cells were given weekly for 10 weeks along with interleukin-2.
RESULTS
Three patients were enrolled, and the regimen was well-tolerated, with no GVHD observed. All patients had clinical response, despite advanced and heavily pretreated disease.
CONCLUSION
The above-outlined protocol demonstrates favorable tolerability and efficacy, and appears to be feasible in the community setting. While the optimal chemotherapy, immunostimulation, and irradiation regimens may be further optimized, future investigation appears warranted, and may include community oncology programs.

Citations

Citations to this article as recorded by

Feasibility and Pilot Studies in Palliative Care Research: A Systematic Review
Terry A. Jones, Timothy S. Olds, David C. Currow, Marie T. Williams
Journal of Pain and Symptom Management.2017; 54(1): 139. CrossRef
Irradiation of peripheral blood mononuclear cells with 7.5 Gy X-rays prior to donor lymphocyte infusion inhibits proliferation while preserving cytotoxicity, and improves the effectiveness of HSCT in patients with hematological malignancies
Yong-Qiu Wei, Xi-Nan Cen, Hui-Hui Liu, Yu-Hua Sun, Yong-Jin Shi, Wei Liu, Yu-Jun Dong, Han-Yun Ren
Oncology Letters.2017; 13(6): 4101. CrossRef

11,039 View
57 Download
2 Crossref

First
Prev
Page of 1
Next
Last